BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 39.6% in December

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 50,400 shares, a decline of 39.6% from the December 15th total of 83,400 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 48,500 shares, the short-interest ratio is presently 1.0 days.

BioCardia Stock Performance

BCDA traded up $0.06 during trading on Wednesday, reaching $2.22. 32,747 shares of the stock were exchanged, compared to its average volume of 39,623. The stock’s 50 day moving average price is $2.19 and its two-hundred day moving average price is $2.58. BioCardia has a twelve month low of $1.63 and a twelve month high of $9.90. The stock has a market cap of $10.18 million, a P/E ratio of -0.53 and a beta of 1.26.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.